First Author: M.Sabaner TURKEY
Co Author(s): M. Dogan
Back to previous
To evaluate the early efficacy of aflibercept in patients with naive diabetic macular edema.
Afyon Kocatepe University, Faculty of Medicine, Department of Ophthalmology, Afyonkarahisar, Turkey
In this retrospective study, diabetic macular edema naive eyes who were treated with aflibercept (Eylea® 40mg/ml Bayer, Germany) intravitreal injections from 01/09/2016 to 31/02/2017 were evaluated. Follow-up time was 4,30±1,06 months. Aflibercept was administrated as initial 3 consecutive monthly injections, with control examination after 3 injections. The main outcome measures were the change in best corrected visual acuity (BCVA), the central macular thickness (CMT), total macular volume (TMV), central subfield volume (CSV) and choroidal thickness (CT) measured with spectral-domain ocular tomography coherence (SD-OCT).
33 eyes from 23 diabetic patients were enrolled. The mean age was 59.03±7.93 years old and the majority of patients were female (57%). Mean BCVA at baseline was 0.72 ± 0.27 LogMAR. It changed to 0.62 ± 0.18 LogMAR (p:0.122) at third month. Mean CMT at baseline was 380.73±174.94 µm. It changed to 258.24± 66.5 µm (p<0.001) at third month. Mean TMV at baseline was 10.07±1.74 mm3. It changed to 9.08±1.20 mm3 (p<0.001) at third month. Mean CSV at baseline was 0.32±0.12 mm3. It changed to 0.24±0.06 mm3 (p<0.001) at third month. Mean CT at baseline was 156.39±25.80 µm. It changed to 149.7±26.70 µm (p:0.314) at third month. During the selected period, patients received a mean of 3.06±0.24 injections.
Intravitreal aflibercept injection appears effective in management of diabetic macular edema. Functional and anatomic improvement was obvious in 3 months after injection.